CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM051036
Első szerző:Póka Róbert (szülész-nőgyógyász, klinikai onkológus)
Cím:Pattern of pill-switch in oral contraception / Póka R., Vad S.
Dátum:2002
Megjegyzések:Pattern of pill-switch in oral contraceptionPóka R., Vad S. Department of Obstetrics and Gynecology, University of Debrecen Medical Health Science Center Introduction: The aim of the study was to observe the pattern of pill- switch among oral contraceptive users. Patients and methods: Cross- sectional study of 1108 women attending regular gynecological screening examination. Women were randomly selected to be entered into survey. Age, type of currently used pill, date of start of use, type of previously used pill, date of start and stop of its use were recorded in a standard questionnaire. Time interval between stopping the previously used and starting the currently used pill were computed as well as duration of use.Results: 949 (85.6%) women had used at least one type of oral contraceptives. 58.8% (652 cases) of the total population was on the pill at the time of the survey. Among current users who had been on pill for at least 3 months (long- term users) 26% had switched from a brand with different estrogen content. 59% of those who switched their pill within 12 months of use (short- term switchers) had switched from a brand that had different estrogen content. With regard to the progestogen component, 48% of long- term users and 66% of short- term switchers had switched to different formulation. Conclusion: Symptoms tt raise the need for changing the pill are more often relieved by starting another formulation with different progestogen component rather than one with different estrogen content.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
oral contraception
pill switch
Megjelenés:Ceska Gynekologia. - 67 : Suppl. 2 (2002), p. 70. -
További szerzők:Vad Szilvia (1976-) (nőgyógyász)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM051034
Első szerző:Vad Szilvia (nőgyógyász)
Cím:Sensitivity to activated protein C as a measure of women's reproductive health / Vad S., Póka R., Ajzner É.
Dátum:2002
Megjegyzések:Introduction: Evaluation of screening for resistance to activated protein C in estimating the risk of thromboembolism during oral contraceptive use, infertility and miscarriage in a general population of women.Patients and methods: Activated protein C (APC) resistance assay was performed in 3140 women with commercially available functional test kits. Personal and family history thromboembolic disease and occurrence of miscarriage and infertility were compared between patient with sensitivity of APC below and above mean -1SD. The thromboembolic risk calculation was stratified to past and current oral contraceptive users. Results: The mean activated protein C sensitivity rate (APCSR) was 2.368 (min.=1.07, max=3.98, SD=0.438. Oral contraceptive users had a significantly lower APCSR than non-users (2.173 vs.2.33 p<0.05). 10.91% (317 cases) of the total study population had an APCSR below the mean -1 SD (<1.93, APC- resistants). The risk of miscarriage was 2.72 times higher among APC- resistants than among sensitives (95% CI 1.61-4.60). APC resistant cases had a relative risk of 4.04 (95% CI1.79-9.14) to experience difficulty to conceiving. Thromboembolism occurred 2.54 times more frequently (95% CI 1.85-3.48) in the family of APC resistant cases than in those sensitives, and 3.72 times more frequently (95%CI 1.86-7.41) among APC resistant cases themselves than among sensitives. The relative risk of thromboembolism among APC resistant past oral contraceptive users was 2.51 (95% CI 1.06-5.95), while that among current users was 25.8 (95% CI 3.14-221.6).Conclusion: Screening to resistance of activated protein C in general population with high allelic frequency of the Leiden- mutation may help to select women at risk of reduced reproductive health. Correct patient information regarding thromboembolic risk may help to improve safety of oral contraceptive use.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
activated protein C
reproductive health
Megjelenés:Ceska Gynekologia. - 67 : Suppl. 2 (2002), p. 34. -
További szerzők:Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Ajzner Éva (1968-) (laboratóriumi szakorvos)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM051035
Első szerző:Vad Szilvia (nőgyógyász)
Cím:Antiphospholipid antibodies in young women with and without oral contraceptive use / Vad S., Lakos G., Kiss E., Sipka S., Csorba R., Póka R.
Dátum:2002
Megjegyzések:Introduction: Antiphospholipid antibodies are associated with arterial and venosus thrombosis and recurrent pregnancy loss. High titre of antiphospholipid antibodies has been shown to associated with increased risk for future ischemic stroke, venosus thrombosis and myocardial infarction in men. In this study, we analysed the occurence of antiphospholipid antibodies among asymptomatic young women with and without oral contraceptive use. Patients and methods: We performed a cross-sectional study among 223 apparently healthy, non-pregnant, young women to survey the occurence of antiphospholipid antibodies among users and non- users of OC. Serum levels of IgG, IgA and IgM isotypes of anti-b2-glycoprotein I and anticardiolipin antibodies were measured by validated ELISA methods. Means of continuous variables in the two study groups were compared my c2- test. Differences in the frequency of abnormal results were expressed by odds- ratio and 95% confidence intervals were generated for the assessment of statistical significance. Results: There were no statistically significant differences between pill- users and non-users in age, total length of past gestation, frequency of miscarriage or infertility, family history of deep vein thrombosis and the day of menstrual cycle on which blood was drawn. Combining all types of antiphospholipid antibodies, pill- users had an elevated antibody titre more than twice as frequently than non-users (OR=2.3, 95% CI 1.1-5.1). The hogher frequency of elevated antibody titre was related most commonly to IgG type anti-b2-glycoprotein I antibodies. Conclusion: Oral contraceptive use increases the risk of elevated antiphospholipid antibody levels among asymptomatic young women. Further studies are needed to assess longitudinal changes in antiphospholipid antibody levels during oral contraception.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
antiphospholipid antibody
contraception
women
Megjelenés:Ceska Gynekologia. - 67 : Suppl. 2 (2002), p. 34. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus) Sipka Sándor (1945-) (laboratóriumi szakorvos) Csorba Roland (1972-) (szülész-nőgyógyász, gyermeknőgyógyász) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1